Galecto, Inc.

Equities

GLTO

US36322Q1076

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-27 pm EDT 5-day change 1st Jan Change
0.78 USD +3.38% Intraday chart for Galecto, Inc. -1.14% +8.33%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Galecto, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Galecto Shares Climb After Bone Marrow Disease Treatment Trial Yields Positive Results MT
Galecto, Inc. Announces Positive Topline Results from A Phase 2A Trial of GB2064 for the Treatment of Myelofibrosis CI
Galecto, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Galecto, Inc. Presents Updated Clinical Data At ESMO Congress 2023 and Provides Update on Phase 1B/2A Gallant-1 Trial CI
HC Wainwright Downgrades Galecto to Neutral From Buy MT
Galecto Announces Plans to Explore Strategic Alternatives CI
Galecto to Explore Strategic Options, to Reduce Workforce MT
Galecto, Inc. Announces Executive Changes, Effective October 1, 2023 CI
Galecto, Inc. Proposes to Reduce Its Workforce by 29 People, or Approximately 70% of the Existing Headcount CI
HC Wainwright Adjusts Price Target on Galecto to $2 From $12, Maintains Buy Rating MT
Sector Update: Health Care Stocks Declining in Late Afternoon Trading MT
Sector Update: Health Care Stocks Easing Tuesday Afternoon MT
Top Midday Decliners MT
Galecto to End Lung Disease Drug Development After Trial Failed to Meet Primary Endpoint; Shares Fall MT
Galecto to discontinue development of lung disease treatment RE
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis CI
Galecto, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Oppenheimer Initiates Coverage on Galecto With Outperform Rating, $12 Price Target MT
Galecto Completes Patient Dosing in Mid-Stage Trial of Lung Disease Drug Candidate MT
Galecto, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Cantor Fitzgerald Initiates Galecto at Overweight With $16 Price Target MT
Galecto, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Earnings Flash (GLTO) GALECTO Posts Q3 Loss $-0.54 MT
Galecto, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Chart Galecto, Inc.
More charts
Galecto, Inc. is a clinical-stage biotechnology company. The Company is focused on developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The Company's initial focus is on the development of small molecule inhibitors of galectin-3 and lysyl oxidase-like 2 (LOXL2). The Company is developing GB0139 for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a life-threatening progressive fibrotic disease of the lung. The Company's product candidate also includes GB1211, a selective oral small molecule inhibitor of galectin-three, is chemically distinct from GB0139 and is being developed for the treatment of various oncology indications and liver cirrhosis, and GB2064 is a selective oral small molecule inhibitor of LOXL2 for the treatment of myelofibrosis, a malignant disease of the bone marrow in which progressive fibrosis reduces the ability to form blood cells in the bone marrow.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
0.78 USD
Average target price
6 USD
Spread / Average Target
+669.23%
Consensus
  1. Stock
  2. Equities
  3. Stock Galecto, Inc. - Nasdaq
  4. News Galecto, Inc.
  5. Sector Update: Health Care Stocks Mixed Ahead of Tuesday Close